Stock Analysis

Investor Optimism Abounds Salesforce, Inc. (NYSE:CRM) But Growth Is Lacking

You may think that with a price-to-sales (or "P/S") ratio of 7.6x Salesforce, Inc. (NYSE:CRM) is a stock to avoid completely, seeing as almost half of all the Software companies in the United States have P/S ratios under 4.3x and even P/S lower than 1.6x aren't out of the ordinary. Although, it's not wise to just take the P/S at face value as there may be an explanation why it's so lofty.

View our latest analysis for Salesforce

ps-multiple-vs-industry
NYSE:CRM Price to Sales Ratio vs Industry May 5th 2024

What Does Salesforce's P/S Mean For Shareholders?

Recent times haven't been great for Salesforce as its revenue has been rising slower than most other companies. One possibility is that the P/S ratio is high because investors think this lacklustre revenue performance will improve markedly. However, if this isn't the case, investors might get caught out paying too much for the stock.

Want the full picture on analyst estimates for the company? Then our free report on Salesforce will help you uncover what's on the horizon.

Is There Enough Revenue Growth Forecasted For Salesforce?

There's an inherent assumption that a company should far outperform the industry for P/S ratios like Salesforce's to be considered reasonable.

If we review the last year of revenue growth, the company posted a worthy increase of 11%. This was backed up an excellent period prior to see revenue up by 64% in total over the last three years. Therefore, it's fair to say the revenue growth recently has been superb for the company.

Turning to the outlook, the next three years should generate growth of 10% per annum as estimated by the analysts watching the company. With the industry predicted to deliver 15% growth per year, the company is positioned for a weaker revenue result.

With this information, we find it concerning that Salesforce is trading at a P/S higher than the industry. It seems most investors are hoping for a turnaround in the company's business prospects, but the analyst cohort is not so confident this will happen. Only the boldest would assume these prices are sustainable as this level of revenue growth is likely to weigh heavily on the share price eventually.

What We Can Learn From Salesforce's P/S?

Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.

Despite analysts forecasting some poorer-than-industry revenue growth figures for Salesforce, this doesn't appear to be impacting the P/S in the slightest. When we see a weak revenue outlook, we suspect the share price faces a much greater risk of declining, bringing back down the P/S figures. Unless these conditions improve markedly, it's very challenging to accept these prices as being reasonable.

It's always necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Salesforce, and understanding these should be part of your investment process.

If these risks are making you reconsider your opinion on Salesforce, explore our interactive list of high quality stocks to get an idea of what else is out there.

Mobile Infrastructure for Defense and Disaster

The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.

Get the investor briefing before the next round of contracts

Sponsored On Behalf of CiTech

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NYSE:CRM

Salesforce

Provides customer relationship management technology that connects companies and customers together worldwide.

Good value with adequate balance sheet.

Weekly Picks

WO
MGPI logo
woodworthfund on MGP Ingredients ·

THE KINGDOM OF BROWN GOODS: WHY MGPI IS BEING CRUSHED BY INVENTORY & PRIMED FOR RESURRECTION

Fair Value:US$4034.1% undervalued
22 users have followed this narrative
1 users have commented on this narrative
5 users have liked this narrative
DO
Double_Bubbler
EVTL logo
Double_Bubbler on Vertical Aerospace ·

Why Vertical Aerospace (NYSE: EVTL) is Worth Possibly Over 13x its Current Price

Fair Value:US$6089.9% undervalued
22 users have followed this narrative
3 users have commented on this narrative
17 users have liked this narrative
TI
TickerTickle
ORCL logo
TickerTickle on Oracle ·

The Quiet Giant That Became AI’s Power Grid

Fair Value:US$389.8149.0% undervalued
43 users have followed this narrative
4 users have commented on this narrative
8 users have liked this narrative

Updated Narratives

AG
Agricola
EXN logo
Agricola on Excellon Resources ·

A case for CA$31.80 (undiluted), aka 8,616% upside from CA$0.37 (an 86 bagger!).

Fair Value:CA$31.898.8% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
ST
stuart_roberts
UNCY logo
stuart_roberts on Unicycive Therapeutics ·

Unicycive Therapeutics (Nasdaq: UNCY) – Preparing for a Second Shot at Bringing a New Kidney Treatment to Market (TEST)

Fair Value:US$21.5370.2% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
KI
RKLB logo
KiwiInvest on Rocket Lab ·

Rocket Lab USA Will Ignite a 30% Revenue Growth Journey

Fair Value:US$97.8335.1% undervalued
137 users have followed this narrative
8 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

TH
TheWallstreetKing
MVIS logo
TheWallstreetKing on MicroVision ·

MicroVision will explode future revenue by 380.37% with a vision towards success

Fair Value:US$6098.4% undervalued
120 users have followed this narrative
11 users have commented on this narrative
22 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$250.3927.7% undervalued
963 users have followed this narrative
6 users have commented on this narrative
25 users have liked this narrative
RO
RockeTeller
SCZ logo
RockeTeller on Santacruz Silver Mining ·

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)

Fair Value:CA$8688.0% undervalued
78 users have followed this narrative
8 users have commented on this narrative
21 users have liked this narrative